Skip to content

Unity Biotech down on stumble with lead drug

August 17, 2020

Unity Biotechnology’s (NASDAQ:UBX) lead candidate UBX0101, a p53/MDM2 interaction inhibitor, failed to sufficiently separate from placebo at week 12 in a Phase 2 clinical trial in patients with moderate-to-severe osteoarthritis of the knee. Specifically, there was no statistically significant difference between any of the three dose arms and the control arm as measured by the primary endpoint, a scale called WOMAC-A.

The company does not expect to advance UBX0101 into pivotal studies, opting instead to concentrate on its ophthalmologic and neurologic disease programs.

The results will be submitted for presentation at a future medical conference.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: